The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease
Clinical Kidney Journal · 04.03.2025 · 18 (3)
DOI: 10.1093/ckj/sfaf039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 08.02.2025. Verfasst von Zewei Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Changzheng Hospital, Naval Medical University, Shanghai, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Research Project of Shanghai Municipal Health Commission, Oriental Talent Plan Outstanding Program 2023, the Shanghai Municipal Key Clinical Specialty.
Abstract (Originalsprache)
Background
Obinutuzumab, a new-generation anti-CD20 monoclonal antibody, was originally developed to overcome resistance to rituximab in B-cell malignancies. There is limited research regarding the use of obinutuzumab in patients with rituximab-refractory membranous nephropathy (MN) and minimal change disease (MCD).
Methods
A retrospective analysis was performed at Changzheng Hospital from September 2022 to September 2024, and screened patients with rituximab-refractory MN or MCD. Participants were treated because they were refractory to rituximab and consented to receive infusions of obinutuzumab. Primary outcomes were defined as complete remission (CR, proteinuria <0.3 g/d) or partial remission (PR, proteinuria <3.5 g/d with a ≥50% reduction). Secondary outcome was immunological remission in patients with phospholipase A2 receptor (PLA2R)-related MN.
Results
Seven patients with MN and five with MCD were included in the cohort. Among patients with MN, six of seven (86%) achieved at least PR, of whom two patients reached CR with a median time to first remission (either PR or CR) of 8.0 months. Among patients with positive serum anti-PLA2R antibodies at baseline, all achieved an immunological response. No patients experienced a relapse during the follow-up period. Among patients with MCD, all patients achieved a CR with the median time of 1.0 months. Patients who were steroid-dependent or immunosuppressant-dependent were able to taper their medications in the short term without experiencing relapse. No treatment-related severe adverse events were reported.
Conclusions
Our study demonstrated that obinutuzumab represents a promising alternative therapeutic option for the management of rituximab-refractory MN and MCD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Changzheng Hospital, Naval Medical University, Shanghai, China.
- Department of Nephrology, The First Navy Hospital of Southern Theater Command, Zhanjiang, Guangdong, China.
- Department of Cardiology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Clinical Research Project of Shanghai Municipal Health Commission
- Oriental Talent Plan Outstanding Program 2023, the Shanghai Municipal Key Clinical Specialty
- Shanghai Shenkang Research Physician innovation and transformation ability training program
- Scientific and technological innovation action plan of Shanghai medical innovation research special project
- Science and Technology Research Plan of Zhanjiang
Zitieren
APA
Chen, Z., Xu, D., Wu, S., Liu, W., Wu, J., Yu, S., Dai, B., Mao, Z., & Gao, X. (2025). The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease. Clinical Kidney Journal, 18(3). https://doi.org/10.1093/ckj/sfaf039
Vancouver
Chen Z, Xu D, Wu S, Liu W, Wu J, Yu S, et al. The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease. Clinical Kidney Journal. 2025;18(3). doi:10.1093/ckj/sfaf039
BibTeX
@article{Chen2025,
author = {Chen, Zewei and Xu, Dechao and Wu, Shuangcheng and Liu, Wenyu and Wu, Jianxiang and Yu, Shengqiang and Dai, Bing and Mao, Zhiguo and Gao, Xiang},
title = {The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease},
journal = {Clinical Kidney Journal},
year = {2025},
volume = {18},
number = {3},
doi = {10.1093/ckj/sfaf039}
}
EUVIMED